Pay in 4 interest-free payments of $7.43 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Reasonable candidates include: Mild to moderate IBD as an adjunct (never as sole therapy, always with GI oversight) IBS with a documented inflammatory component Post-infectious gut dysfunction where both tissue damage and persistent low-grade inflammation are present Mixed presentations, heartburn plus intestinal sensitivity plus food reactivity, where the clinical picture suggests multiple mechanisms Where this falls apart is when people treat it as a silver bullet
Swab the top of the vial with 95% alcohol wipe before accessing
The four components span distinct structural classes and non-overlapping pathway layers signaling, ECM remodeling, cytoskeleton, and inflammation
Neither BPC-157 nor TB-500 has received FDA approval for human use, placing them in the category of research compounds without official safety data in humans
Peptides like BPC-157 may help bridge that gap
